Immunovant Inc (IMVT) Ganando

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. The company is headquartered in New York City, New York and currently employs 362 full-time employees. The company went IPO on 2019-05-14. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The firm is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).